{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:44:33Z","timestamp":1790603073854,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&amp;D Program of China","doi-asserted-by":"publisher","award":["2024YFC2309804"],"award-info":[{"award-number":["2024YFC2309804"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Considering the absence of a widely utilized EBV vaccine, we have developed an EBV gL-gH344-Ferritin nanoparticle vaccine utilizing ferritin as a carrier. The gL-gH344-Ferritin fusion gene was synthesized and inserted into the pET30a plasmid. The expression of the fusion protein in the recombinant plasmid was verified by Western blot. Then, the gL-gH344-Ferritin subunit nanoparticle vaccine was obtained by purification of the fusion protein. BALB\/c mice were immunized using a two-dose protocol. The titers of EBV specific antibodies were determined using enzyme-linked immunosorbent assay at 4, 8, and 12 weeks after the initial immunization. Moreover, the levels of EBV gL-gH344 specific splenocytes secreting interferon (IFN)-\u03b3 and interleukin (IL)-6 were determined using an enzyme-linked immunospot assay. The pET30a-gL-gH344-Ferritin prokaryotic expression plasmid was successfully constructed. gL-gH344-Ferritin was efficiently expressed in E. coli. Following immunization with gL-gH344-Ferritin, the mice sera demonstrated elevated titers of EBV specific immunoglobulin G. Moreover, after stimulating with EBV gL-gH344 specific peptides, the splenocytes of the immunized mice showed a marked tendency to secrete large amounts of IFN-\u03b3 and IL-6. The gL-gH344-Ferritin nanoparticle vaccine carrying the EBV gL-gH344 fusion protein induced robust and sustained specific humoral and cellular immune responses in mice.<\/jats:p>","DOI":"10.3390\/v17060754","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:49:52Z","timestamp":1748234992000},"page":"754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EBV gL-gH344-Ferritin Nanoparticle Vaccine Elicits Robust Immune Responses in Mice"],"prefix":"10.3390","volume":"17","author":[{"given":"Chenyu","family":"Li","sequence":"first","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"},{"name":"Hebei Key Laboratory for Chronic Diseases, School of Basic Medicine Sciences, North China University of Science and Technology, Tangshan 063210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Cao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ma","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4790-1300","authenticated-orcid":false,"given":"Ke","family":"Xu","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Li","sequence":"additional","affiliation":[{"name":"Hebei Key Laboratory for Chronic Diseases, School of Basic Medicine Sciences, North China University of Science and Technology, Tangshan 063210, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0111-9826","authenticated-orcid":false,"given":"Yanzhe","family":"Hao","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Feng","sequence":"additional","affiliation":[{"name":"National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Chakravorty, S., Afzali, B., and Kazemian, M. (2022). EBV-associated diseases: Current therapeutics and emerging technologies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1059133"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cruz-Mu\u00f1oz, M.E., and Fuentes-Panan\u00e1, E.M. (2017). Beta and Gamma Human Herpesviruses: Agonistic and Antagonistic Interactions with the Host Immune System. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02521"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","article-title":"Infectious mononucleosis","volume":"362","author":"Luzuriaga","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cai, J., Zhang, B., Li, Y., Zhu, W., Akihisa, T., Li, W., Kikuchi, T., Liu, W., Feng, F., and Zhang, J. (2021). Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction. Vaccines, 9.","DOI":"10.3390\/vaccines9111290"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.01.010","article-title":"gH\/gL supercomplexes at early stages of herpesvirus entry","volume":"18","author":"Heldwein","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1128\/JVI.72.7.5552-5558.1998","article-title":"Epstein-Barr Virus Uses Different Complexes of Glycoproteins gH and gL To Infect B Lymphocytes and Epithelial Cells","volume":"72","author":"Wang","year":"1998","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bu, G.L., Xie, C., Kang, Y.F., Zeng, M.S., and Sun, C. (2022). How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection. Viruses, 14.","DOI":"10.3390\/v14112372"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Sun, C., Chen, X.C., Kang, Y.F., and Zeng, M.S. (2021). The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.677027"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rong, H., Qi, M., Pan, J., Sun, Y., Gao, J., Zhang, X., Li, W., Zhang, B., Zhang, X.E., and Cui, Z. (2022). Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.905431"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/acsnano.0c08379","article-title":"Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates","volume":"15","author":"Kang","year":"2021","journal-title":"ACS Nano"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41591-021-01660-8","article-title":"Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: A phase 1 trial","volume":"28","author":"Houser","year":"2022","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100658","DOI":"10.1016\/j.xcrm.2022.100658","article-title":"Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge","volume":"3","author":"Malhi","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.xcrm.2024.101587","article-title":"Vaccination with nanoparticles displaying gH\/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus","volume":"5","author":"Edwards","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): A comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_16","first-page":"500","article-title":"Identification of the T-cell Epitope in BALB\/c Mice Immunized with Adenovirus Vector EBV Vaccine Expressing gH\/gL Antigen","volume":"40","author":"Shi","year":"2024","journal-title":"Virus Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.tim.2023.03.001","article-title":"Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents","volume":"31","author":"Zhong","year":"2023","journal-title":"Trends Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1128\/JVI.03032-15","article-title":"Comparative Mutagenesis of Pseudorabies Virus and Epstein-Barr Virus gH Identifies a Structural Determinant within Domain III of gH Required for Surface Expression and Entry Function","volume":"90","author":"Klupp","year":"2016","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13570","DOI":"10.1128\/JVI.02272-14","article-title":"The conserved disulfide bond within domain II of Epstein-Barr virus gH has divergent roles in membrane fusion with epithelial cells and B cells","volume":"88","author":"Sathiyamoorthy","year":"2014","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2004.03.029","article-title":"Evaluation of T helper-1\/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis","volume":"44","author":"Kawasaki","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-024-00907-y","article-title":"A gH\/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge","volume":"9","author":"Edwards","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/s41467-024-49546-w","article-title":"A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection","volume":"15","author":"Zhong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00062752-200101000-00009","article-title":"Th1 and Th2 cells","volume":"8","author":"Dong","year":"2001","journal-title":"Curr. Opin. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Li, P., Jiang, Z., Shi, J., Sha, H., Yu, Z., Zhao, Y., Han, S., and Ma, L. (2024). A self-assembled nanoparticle vaccine elicits effective neutralizing antibody response against EBV infection. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1530364"},{"key":"ref_25","unstructured":"S\u00e1ndor, K. (2018). Parasitism in Goats: Husbandry Management, Range Management, Gut Immunity and Therapeutics. Goat Science, IntechOpen. Chapter 13."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_27","first-page":"7578","article-title":"Positive correlation between VCA-IgM and Th1\/Th2 immunocytokines in children with infectious mononucleosis","volume":"14","author":"Yang","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.vaccine.2018.12.029","article-title":"The views of key stakeholders around mandatory influenza vaccination of hospital and aged care staff: Examining the current climate in Australia","volume":"37","author":"Moran","year":"2019","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1038\/s41467-022-32854-4","article-title":"X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation","volume":"13","author":"Lee","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Arvin, A., Campadelli-Fiume, G., Mocarski, E., Moore, P.S., Roizman, B., Whitley, R., and Yamanishi, K. (2007). EBV: Immunobiology and host response. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge University Press.","DOI":"10.1017\/CBO9780511545313"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Todorovi\u0107, N., Ambrosio, M.R., and Amedei, A. (2024). Immune Modulation by Epstein\u2013Barr Virus Lytic Cycle: Relevance and Implication in Oncogenesis. Pathogens, 13.","DOI":"10.3390\/pathogens13100876"},{"key":"ref_33","first-page":"516","article-title":"Cancer vaccine designed from homologous ferritin-based fusion protein with enhanced DC-T cell crosstalk for durable adaptive immunity against tumors","volume":"46","author":"Wu","year":"2025","journal-title":"Bioact. Mater."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yoshida, S., Yamada, S., Yokose, K., Matsumoto, H., Fujita, Y., Asano, T., Matsuoka, N., Temmoku, J., Sato, S., and Yoshiro-Furuya, M. (2021). Interferon-\u03b3 induces interleukin-6 production by neutrophils via the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. BMC Res. Notes, 14.","DOI":"10.1186\/s13104-021-05860-w"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Cui, X., and Snapper, C.M. (2021). Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.734471"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Li, Y., Tian, S., Ai, Y., Hu, Z., Ma, C., Fu, M., Xu, Z., Li, Y., Liu, S., and Zou, Y. (2024). A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1419634"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Behrens, M., Comabella, M., and L\u00fcnemann, J.D. (2024). EBV-specific T-cell immunity: Relevance for multiple sclerosis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1509927"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet","year":"2021","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:40:18Z","timestamp":1760031618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/6\/754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["v17060754"],"URL":"https:\/\/doi.org\/10.3390\/v17060754","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}